Pf-08046033

Phase 1

Pfizer

Pf-08046033 is one of 3 therapeutic programs targeting Non-Small-Cell Lung. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Non-Small-Cell LungRecruiting

Non-Small-Cell LungPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Non-Small-Cell Lung

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 3

1 2

Savolitinib

AstraZeneca

Phase 3

1 3

Pf-08046033

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Non-Small-Cell Lung

NCT07519655

Clinical

Trials by Indication[1]

Non-Small-Cell Lung1 trial

A Phase 1 Study to Investigate PF-08046033 in Participants With Advanced Solid Tumors

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07519655·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pf-08046033. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pf-08046033. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Pfizer

Pf-08046033

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News